Home » Stocks » ETNB

89bio, Inc. (ETNB)

Stock Price: $24.17 USD 0.06 (0.25%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 500.27M
Revenue (ttm) n/a
Net Income (ttm) -49.50M
Shares Out 20.03M
EPS (ttm) -72.33
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $24.17
Previous Close $24.11
Change ($) 0.06
Change (%) 0.25%
Day's Open 24.16
Day's Range 23.88 - 24.97
Day's Volume 27,540
52-Week Range 18.01 - 42.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

- Received written guidance from FDA related to trial design and agreement to use liquid formulation - - ENLIVEN trial to initiate as planned in 2Q21 -

1 month ago - GlobeNewsWire

- Initiation of BIO89-100 Phase 2b NASH trial planned in 1H21 -

1 month ago - GlobeNewsWire

New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients with NASH New analysis shows BIO89-100 meaningfully reduces liver fat volume and liver volume in patients ...

1 month ago - GlobeNewsWire

SAN FRANCISCO, March 11, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the ...

1 month ago - GlobeNewsWire

SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

2 months ago - GlobeNewsWire

BIO89-100 is lead and only molecule targeting NASH with superior early-stage data. Among its peer group, molecule is well differentiated.

3 months ago - Seeking Alpha

SAN FRANCISCO, Jan. 04, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

4 months ago - GlobeNewsWire

SAN FRANCISCO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the t...

5 months ago - GlobeNewsWire

– Data demonstrated compelling efficacy profile and favorable tolerability with weekly and every two-week dosing –

5 months ago - GlobeNewsWire

– Updated clinical data from BIO89-100 's Phase 1b/2a NASH trial to be presented as a late-breaking poster at upcoming AASLD Liver Meeting –

5 months ago - GlobeNewsWire

SAN FRANCISCO, Sept. 28, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

7 months ago - GlobeNewsWire

SAN FRANCISCO, Sept. 16, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

7 months ago - GlobeNewsWire

SAN FRANCISCO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

7 months ago - GlobeNewsWire

All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo    

7 months ago - GlobeNewsWire

SAN FRANCISCO, Sept. 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study o...

7 months ago - GlobeNewsWire

- Multi-center, randomized, double-blind, placebo-controlled study will evaluate the safety and efficacy of BIO89-100 administered weekly or every two weeks for 8 weeks - - Multi-center, randomized, dou...

8 months ago - GlobeNewsWire

- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in Late Q3 to Early Q4 -

8 months ago - GlobeNewsWire

89bio (ETNB) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

8 months ago - Zacks Investment Research

Let us take a look at some biotech stocks that are poised to beat on second-quarter earnings.

Other stocks mentioned: ARCT, AVRO, FULC, ICPT
9 months ago - Zacks Investment Research

SAN FRANCISCO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...

9 months ago - GlobeNewsWire

SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...

9 months ago - GlobeNewsWire

89bio (ETNB) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

SAN FRANCISCO, June 04, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the...

11 months ago - GlobeNewsWire

- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in 2H20 -

11 months ago - GlobeNewsWire

- Closed enrollment in its Phase 1b/2a NASH trial with 98% of patients enrolled and delays initiation of its SHTG trial due to the COVID-19 pandemic; Reaffirms guidance for NASH trial topline data in 2H...

1 year ago - GlobeNewsWire

SAN FRANCISCO, March 25, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for th...

1 year ago - GlobeNewsWire

About ETNB

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop BIO89-100 for the treatment of severe hypertriglyceridemia. 89bio, Inc. was founded in 2018 and is based in San Francisco, California.

Industry
Biotechnology
IPO Date
Nov 11, 2019
Stock Exchange
NASDAQ
Ticker Symbol
ETNB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for 89bio stock is "Strong Buy." The 12-month stock price forecast is 60.00, which is an increase of 148.24% from the latest price.

Price Target
$60.00
(148.24% upside)
Analyst Consensus: Strong Buy